Corvus Pharmaceuticals, Inc.(NASDAQ : CRVS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||-0.23%||164.48||0.7%||$988.09m|
|MRK||Merck & Co., Inc.||0.81%||73.64||0.7%||$914.30m|
|LLY||Eli Lilly & Co.||-0.26%||231.58||1.1%||$588.95m|
|BMY||Bristol-Myers Squibb Co.||-0.61%||60.26||1.0%||$575.61m|
|CRVS||Corvus Pharmaceuticals, Inc.||-3.27%||6.80||0.7%||$140.27m|
|RPRX||Royalty Pharma Plc||-0.08%||37.10||0.1%||$121.13m|
|NVO||Novo Nordisk A/S||-1.36%||100.71||0.1%||$101.76m|
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancerâ€™s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.